基于多靶点粪便FIT-DNA联合检测技术的结直肠癌早筛应用研究OACSTPCD
Application of Colorectal Cancer Early Screening Based on Multitarget Fecal FIT-DNA Joint Detection Technology
目的 评价多靶点粪便FIT-DNA联合检测技术在结直肠癌早期筛查中的效果并进一步分析其应用前景.方法 选取内蒙古医科大学附属医院就诊人群,每位受试者分别行血清肿瘤标志物检测、多靶点粪便FIT-DNA联合检测、肠镜检查,以接受多靶点粪便FIT-DNA联合检测人群为实验组,以接受肠镜检查及血清肿瘤标志物检测人群为对照组,以病理结果为金标准,评价新型粪便分子检测技术对于结直肠癌筛查的效果,对筛出的阳性人群给予及时干预.结果 共分析了115例患者.血清肿瘤标志物检测敏感度63.2%(43/68),特异度74.5%(35/47);肠镜检查敏感度97.1%(66/68),特异度80.7%(38/47);而多靶点粪便FIT-DNA联合检测敏感度89.7%(61/68),特异度87.2%(41/47).多靶点粪便FIT-DNA联合检测敏感度、特异度等均优于血清肿瘤标志物检测,敏感度虽低于肠镜检查,但相较肠镜检查操作简单,可居家自测.
Objective To evaluate the efficacy and further analyze the application prospects of the combined multitarget fecal FIT-DNA assay in the early screening of colorectal cancer.Methods Subjects were selected from a population attending the Inner Mongolia Medical University Hospital.Each subject underwent a combined multi-target fecal FIT-DNA test(experimental group),a serum tumor marker test and enteroscopy(control group).The pathological results were used as the gold standard to evaluate the efficacy of novel fecal molecular testing techniques for colorectal cancer screening with timely intervention given to screen positive individuals.Results The data of 115 individuals were analyzed.Serum tumor markers test had a sensitivity of 63.2%(43/68)and a specificity of 74.5%(35/47).The enteroscopy had a sensitivity of 97.1%(66/68)and a specificity of 80.7%(38/47);the combined multitarget fecal FIT-DNA test had a sensitivity of 89.7%(61/68)and a specificity of 87.2%(41/47).Conclusion The sensitivity and specificity of multitarget fecal FIT-DNA combined detection are better than those of serum tumor marker detection.Although its sensitivity is lower than enteroscopy,its operation is simpler and can be tested at home.
王杰;侯明星;程海东;刘永强;苗杰;李淑雯;陈璐
010050 呼和浩特,内蒙古医科大学附属医院胃肠外科
临床医学
多靶点粪便FIT-DNA联合检测血清肿瘤标志物结直肠癌早筛肠镜检查
Combined detection of multitarget fecal FIT-DNASerum tumor markersColorectal cancerEarly screeningEnteroscopy
《肿瘤防治研究》 2024 (007)
578-582 / 5
China Cancer Foundation Project(No.NH2018002)中国癌症基金会科研项目(NH2018002)
评论